488 related articles for article (PubMed ID: 15751068)
21. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
[TBL] [Abstract][Full Text] [Related]
22. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
23. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P
J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523
[TBL] [Abstract][Full Text] [Related]
24. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
26. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
Benstead TJ; Chalk CH; Parks NE
Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
Saadoun D; Pol S; Ferfar Y; Alric L; Hezode C; Si Ahmed SN; de Saint Martin L; Comarmond C; Bouyer AS; Musset L; Poynard T; Resche Rigon M; Cacoub P
Gastroenterology; 2017 Jul; 153(1):49-52.e5. PubMed ID: 28288791
[TBL] [Abstract][Full Text] [Related]
28. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
29. PEG-interferon in acute and chronic hepatitis C: a review.
Palumbo E
Am J Ther; 2009; 16(6):573-8. PubMed ID: 19433975
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
[TBL] [Abstract][Full Text] [Related]
31. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
[TBL] [Abstract][Full Text] [Related]
32. Cryoglobulinemia-related vasculitis during effective anti-HCV treatment with PEG-interferon alfa-2b.
De Blasi T; Aguilar Marucco D; Cariti G; Maiello A; De Rosa FG; Di Perri G
Infection; 2008 Jun; 36(3):285-7. PubMed ID: 17962905
[TBL] [Abstract][Full Text] [Related]
33. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
Gragnani L; Visentini M; Fognani E; Urraro T; De Santis A; Petraccia L; Perez M; Ceccotti G; Colantuono S; Mitrevski M; Stasi C; Del Padre M; Monti M; Gianni E; Pulsoni A; Fiorilli M; Casato M; Zignego AL
Hepatology; 2016 Nov; 64(5):1473-1482. PubMed ID: 27483451
[TBL] [Abstract][Full Text] [Related]
35. Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.
Sood A; Midha V; Sood N; Bansal M
Indian J Gastroenterol; 2006; 25(6):283-5. PubMed ID: 17264426
[TBL] [Abstract][Full Text] [Related]
36. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
37. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
38. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha.
Zuckerman E; Keren D; Slobodin G; Rosner I; Rozenbaum M; Toubi E; Sabo E; Tsykounov I; Naschitz JE; Yeshurun D
J Rheumatol; 2000 Sep; 27(9):2172-8. PubMed ID: 10990230
[TBL] [Abstract][Full Text] [Related]
39. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.
Levine JW; Gota C; Fessler BJ; Calabrese LH; Cooper SM
J Rheumatol; 2005 Jun; 32(6):1164-7. PubMed ID: 15940780
[TBL] [Abstract][Full Text] [Related]
40. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
